The authors bring the following errors in their paper  to the attention of readers.
In the third sentence of the first paragraph of the Results on page 337, the percentage of participants who switched to RPV/FTC/TDF should be 96% instead of 94%, and who completed 24 weeks of RPV/FTC/TDF treatment should be 90% instead of 89%.
In Figure 1 on page 338, of the 159 that were randomized to stay on PI+RTV+2NRTIs and received at least one dose, for those that discontinued study before switching to RPV/FTC/TDF for ‘Withdrew consent’ it should be 3 instead of 4, and 1 for an additional reason of ‘Protocol violation’. Of the 152 that switched to RPV/FTC/TDF at week 24, for those that discontinued after switching due to ‘Withdrew consent’ should be 2 instead of 1 and for ‘Protocol violation’ should be 1 instead of 2. The corrected Figure 1 is below.
On page 339, Table 1 the entry for CD4+ cell count (cells/μL) should say ‘Mean (SD)’ and not ‘Median (SD)’.
On page 341, Figure 2 the value for HDL for RPV/FTC/TDF (immediate, D1-W24) should be -4 mg/dl instead of -6 mg/dl and for RPV/FTC/TDF (delayed, W24-W48) should be -2 mg/dl instead of -4 mg/dl. The corrected upper panel of the figure is below.
1. Palella FJ, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014; 28:335–344.